In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process

Thrombosis and Haemostasis

Volumn 109, Issue 1, 2013, Pages 53-60

  Golder, Mia ^a,c   Mewburn, Jeffrey ^b   Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Animal models; Arterial thrombosis; Factor VIII; Intravital microscopy

Indexed keywords

BLOOD CLOTTING FACTOR 8; FIBRIN; THROMBIN ANTITHROMBIN COMPLEX; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY ENDOTHELIUM; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING TEST; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; CREMASTER MUSCLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRIN CLOT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBOELASTOGRAPHY; THROMBOGENICITY;

ANIMALS; ANTITHROMBIN III; BLOOD COAGULATION; CHLORIDES; DISEASE MODELS, ANIMAL; FACTOR VIII; FERRIC COMPOUNDS; HEMOPHILIA A; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE HYDROLASES; THROMBELASTOGRAPHY; THROMBOSIS; TIME FACTORS; UP-REGULATION; VASCULAR SYSTEM INJURIES;

EID: 84872254939     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-05-0316     Document Type: Article

References (40)

1. Vlot AJ, Koppelman SJ, van den Berg MH, et al. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995; 85: 3150-3157.
2. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263: 10451-10455.
3. Monroe DM, Hoffman M, Roberts HR. Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. Blood Coagul Fibrinolysis 1996; 7: 459-464.
4. Butenas S, van 't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 1997; 272: 21527-21533.
5. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512.
6. van Dieijen G, Tans G, Rosing J, et al. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-3442.
7. Orfeo T, Brummel-Ziedins KE, Gissel M, et al. The nature of the stable blood clot procoagulant activities. J Biol Chem 2008; 283: 9776-9786.
8. Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 216-229.
9. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451: 914-918.
10. Bank I, Libourel EJ, Middeldorp S, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3: 79-84.
11. Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
12. Schambeck CM, Grossmann R, Zonnur S, et al. High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII. Thromb Haemost 2004; 92: 42-46.
13. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
14. Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113: 636-642.
15. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-462.
16. Chauhan AK, Kisucka J, Lamb CB, et al. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood 2007; 109: 2424-2429.
17. Cortellaro M, Boschetti C, Cofrancesco E, et al. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscler Thromb 1992; 12: 1063-1070.
18. Tracy RP, Arnold AM, Ettinger W, et al. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 1999; 19: 1776-1783.
19. Meade TW, Cooper JA, Stirling Y, et al. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994; 88: 601-607.
20. Kawasaki T, Kaida T, Arnout J, et al. A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic. Thromb Haemost 1999; 81: 306-311.
21. Machlus KR, Lin FC, Wolberg AS. Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice. Blood 2011; 118: 3960-3968.
22. Bi L, Lawler AM, Antonarakis SE, et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-121.
23. Bi L, Sarkar R, Naas T, et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-3450.
24. Rivard GE, Brummel-Ziedins KE, Mann KG, et al. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3: 2039-2043.
25. Golder M, Pruss CM, Hegadorn C, et al. Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions. Blood 2010; 115: 4862-4869.
26. Shi CX, Graham FL, Hitt MM. A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter. J Gene Med 2006; 8: 442-451.
27. Ye P, Thompson AR, Sarkar R, et al. Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol Ther 2004; 10: 117-126.
28. Amendola M, Venneri MA, Biffi A, et al. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 2005; 23: 108-116.
29. Boisclair MD, Lane DA, Wilde JT, et al. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. Br J Haematol 1990; 74: 471-479.
30. O'Donnell J, Riddell A, Owens D, et al. Role of the Thrombelastograph as an adjunctive test in thrombophilia screening. Blood Coagul Fibrinolysis 2004; 15: 207-211.
31. Reikvam H, Steien E, Hauge B, et al. Thrombelastography. Transfus Apher Sci 2009; 40: 119-123.
32. Sommeijer DW, van Oerle R, Reitsma PH, et al. Analysis of blood coagulation in mice: pre-analytical conditions and evaluation of a home-made assay for thrombin-antithrombin complexes. 2005. Thromb J 2005; 3: 12-21.
33. Furie B, Furie BC. In vivo thrombus formation. J Thromb Haemost 2007; 5: 12-17.
34. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-392.
35. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998; 95: 9524-9529.
36. Brill A. A ride with ferric chloride. J Thromb Haemost 2011; 9: 776-778.
37. Wang L, Miller C, Swarthout RF, et al. Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury. Blood 2009; 113: 705-713.
38. Cao W, Krishnaswamy S, Camire RM, et al. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci USA 2008; 105: 7416-7421.
39. Skipwith CG, Cao W, Zheng XL. Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem 2010; 285: 28596-28603.
40. Cao W, Sabatino DE, Altynova E, et al. Light Chain of Factor VIII Is Sufficient for Accelerating Cleavage of von Willebrand Factor by ADAMTS13 Metalloprotease. J Biol Chem 2012; in press.